|
|
Post by od on Jul 28, 2018 15:48:10 GMT -5
Headquartered in the U.S., Tanner’s reach includes Europe, Northeast Asia, Southeast Asia, the Middle East, Australia, Canada and Latin America, including Brazil, Mexico, the Caribbean, Central America and all of South America. Following is a similar deal. Tanner is based in Charlotte, NC, where MC, the CMO had presentation with UNC, Duke recently. www.tannerpharma.com/tanner-pharma-group-signs-distribution-agreement-partner-therapeutics-product-leukine/Not sure if you were trying to connect Tanner/UNC/Duke geography dots, and hopefully I am not splitting hairs, but...UNC is in Chapel Hill, Duke is in Durham; both are 150 miles from Tanner. |
|
|
|
Post by morgieporgie on Jul 28, 2018 15:50:07 GMT -5
Headquartered in the U.S., Tanner’s reach includes Europe, Northeast Asia, Southeast Asia, the Middle East, Australia, Canada and Latin America, including Brazil, Mexico, the Caribbean, Central America and all of South America. Following is a similar deal. Tanner is based in Charlotte, NC, where MC, the CMO had presentation with UNC, Duke recently. www.tannerpharma.com/tanner-pharma-group-signs-distribution-agreement-partner-therapeutics-product-leukine/Not sure if you were trying to connect Tanner/UNC/Duke geography dots, and hopefully I am not splitting hairs, but...UNC is in Chapel Hill, Duke is in Durham; both are 150 miles from Tanner. Interesting to me that this great news for Mannkind wasn't even newsworthy over at Tanner. |
|
|
|
Post by goyocafe on Jul 28, 2018 15:55:33 GMT -5
Not sure if you were trying to connect Tanner/UNC/Duke geography dots, and hopefully I am not splitting hairs, but...UNC is in Chapel Hill, Duke is in Durham; both are 150 miles from Tanner. Interesting to me that this great news for Mannkind wasn't even newsworthy over at Tanner. I was under the impression their website hadn't been updated since 2014. Could help explain it. |
|
|
|
Post by morgieporgie on Jul 28, 2018 16:01:38 GMT -5
I was under the impression their website hadn't been updated since 2014. Could help explain it. Apparently over there the news ain't really new at all. They got headlines from June 2018. |
|
|
|
Post by tomtabb on Jul 28, 2018 17:00:21 GMT -5
Replying to tomtabb.... You are just seeing part of the conversation. But why am I seeing only part of the conversation? I used to follow the Mannkind Corporation twitter feed, but quit since all they seemed to do was tweet what was already press released. Why don't they use that to publish blurbs about dinners Mike is attending and meetings Dr. Kendall is going to, etc? |
|
|
|
Post by od on Jul 28, 2018 17:32:35 GMT -5
Replying to tomtabb.... You are just seeing part of the conversation. But why am I seeing only part of the conversation? I used to follow the Mannkind Corporation twitter feed, but quit since all they seemed to do was tweet what was already press released. Why don't they use that to publish blurbs about dinners Mike is attending and meetings Dr. Kendall is going to, etc? Really? Please let us know what other public company C-Suite executives are tweeting their day-to-day schedules? (Not targeting you TT, but some posts don't seem to be coming from planet earth. Please excuse the double negative.) |
|
|
|
Post by mnholdem on Jul 28, 2018 18:16:18 GMT -5
Banks is also the founder of Bourne Partners, a leading financial services firm. For over 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jumpstarted his interest in the healthcare sector. Since then, Bourne Partners has been party to more than $10 billion of transactions in pharmaceutical (“pharma”), pharma services and consumer health, and Banks has invested in more than 200 private companies / assets since 2000. Most recently the Bourne Team and other partners co-founded Covis Pharma S.à.r.l. in 2011, successfully helping build and eventually divest the majority of assets in 2015 for $1.2 billion. In late 2015 the firm established Phoenix Therapeutics, Inc., a joint venture with The Carlyle Group. This makes me wonder if there may be non-dilutive financing over the horizon since there may be a vested interest in this Tanner deal becoming lucrative by helping MannKind fund its business plan. |
|
|
|
Post by od on Jul 28, 2018 19:17:54 GMT -5
Banks is also the founder of Bourne Partners, a leading financial services firm. For over 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jumpstarted his interest in the healthcare sector. Since then, Bourne Partners has been party to more than $10 billion of transactions in pharmaceutical (“pharma”), pharma services and consumer health, and Banks has invested in more than 200 private companies / assets since 2000. Most recently the Bourne Team and other partners co-founded Covis Pharma S.à.r.l. in 2011, successfully helping build and eventually divest the majority of assets in 2015 for $1.2 billion. In late 2015 the firm established Phoenix Therapeutics, Inc., a joint venture with The Carlyle Group. This makes me wonder if there may be non-dilutive financing over the horizon since there may be a vested interest in this Tanner deal becoming lucrative by helping MannKind fund its business plan. mn, respectfully, I don't understand? In a best case scenario, how lucrative can the single 'pre-approval' distributor deal be for MannKind? Without ex-us approvals and prescriber support, there is a long road ahead. When other country approvals are complete, will Tanner be the distributor, or is their value limited to direct purchases? |
|
|
|
Post by mnholdem on Jul 28, 2018 20:33:55 GMT -5
Check their website. Read about some of the deals then judge for yourself.  |
|
|
|
Post by tomtabb on Jul 28, 2018 21:31:43 GMT -5
But why am I seeing only part of the conversation? I used to follow the Mannkind Corporation twitter feed, but quit since all they seemed to do was tweet what was already press released. Why don't they use that to publish blurbs about dinners Mike is attending and meetings Dr. Kendall is going to, etc? Really? Please let us know what other public company C-Suite executives are tweeting their day-to-day schedules? (Not targeting you TT, but some posts don't seem to be coming from planet earth. Please excuse the double negative.) Allegedly Mike met with 35 customers. That seems like a fairly large, potentially significant group. Is it all that difficult for the company to tweet about the meeting -- where it took place, who was there, what was discussed, etc? Same with Kendall -- if he's making presentations somewhere, is it all that difficult for a heads up from the company? Maybe some viewer might like to attend. It's not as though the person assigned to do Mannkind tweets is burdened with work, there have been a grand total of three tweets from Mannkind Corp. this month. |
|
|
|
Post by bundy on Jul 28, 2018 23:14:24 GMT -5
 Sorry my wording might not be correct but I think This isn’t trump or the kardashians they really just have to make quarterly reports and run the company not tweet everyday. Jus my 2 cents
|
|
|
|
Post by tomtabb on Jul 29, 2018 8:00:29 GMT -5
Sorry my wording might not be correct but I think This isn’t trump or the kardashians they really just have to make quarterly reports and run the company not tweet everyday. Jus my 2 cents But what else does the investors relations person, Rose Alinaya, have to do all day? There were just two press releases the entire month of July. I don't see how her sitting down a few minutes a day to tweet about things that might not merit a full press release but might attract investors attention could hurt. |
|
|
|
Post by sportsrancho on Jul 29, 2018 8:26:09 GMT -5
Rose doesn’t tweet...oh my goodness. Its the AfrezzaUS people that tweet.
And they are doing fine.
|
|
|
|
Post by mnholdem on Jul 29, 2018 10:35:32 GMT -5
Rose also wears a finance department hat. She held the fort in the interim between Pfeffer’s departure and the hiring of CFO Steve Binder, who she now reports to.
|
|
|
|
Post by mike0475 on Jul 29, 2018 11:13:59 GMT -5
Banks is also the founder of Bourne Partners, a leading financial services firm. For over 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jumpstarted his interest in the healthcare sector. Since then, Bourne Partners has been party to more than $10 billion of transactions in pharmaceutical (“pharma”), pharma services and consumer health, and Banks has invested in more than 200 private companies / assets since 2000. Most recently the Bourne Team and other partners co-founded Covis Pharma S.à.r.l. in 2011, successfully helping build and eventually divest the majority of assets in 2015 for $1.2 billion. In late 2015 the firm established Phoenix Therapeutics, Inc., a joint venture with The Carlyle Group. This makes me wonder if there may be non-dilutive financing over the horizon since there may be a vested interest in this Tanner deal becoming lucrative by helping MannKind fund its business plan. No one else see this potential? Can someone explain how Nate see a 300bagger? I recall you multiply 300 times your investment. Do I have the correct? Even w possible df, banks, and others financing ... 300x??? How Please discuss and happy wing day happy lasagna day and happy lipstick day |
|
Sorry my wording might not be correct but I think This isn’t trump or the kardashians they really just have to make quarterly reports and run the company not tweet everyday. Jus my 2 cents 
